SynthesisFrontiers in cardiovascular medicine2024
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2026Pooled it
- Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2025Pooled it
- Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.Nature medicine · 2026 · on this mapTrial
- Metabolite and nutrient regulation of macrophages in obesity and metabolic disease.Nature reviews. Immunology · 2026Review
- Review
- Met@MPDA rejuvenates BMSC energy metabolism to promote bone regeneration in semaglutide-treated obese periodontitis.Materials today. Bio · 2026Article
- Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.International journal of molecular sciences · 2026Review
- GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory.Comprehensive Physiology · 2026Review
- Impact of Semaglutide as Weight Management Medication on Clinical Parameters and Health-Related Quality of Life: A Single-Center Study from Saudi Arabia.Healthcare (Basel, Switzerland) · 2026Article
- Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.Diabetes, obesity & metabolism · 2026Observational
- Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.International journal of molecular sciences · 2026Review
- Diabetes-Related Metabolic Osteoarthritis: Advanced Glycation-Collagen Axis, Cartilage Stiffening, and Biomaterials-Based Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026Review
- The multifaceted effects of semaglutide: exploring its broad therapeutic applications.Future science OA · 2025Review
- Adipose immune microenvironment: catalyst of age-related adipose tissue dysfunction.Immunity & ageing : I & A · 2025Review
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.Diabetes, obesity & metabolism · 2025Article
- Nonischemic Cardiomyopathy in Adult-Onset PPA2-Deficient Mitochondrial Disease.JACC. Case reports · 2025Article
- Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.Communications medicine · 2025Article
- Article
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.Future cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis. Methods: This meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used. Results: Thirteen randomised clinical trials were considered eligible ( Conclusion: The present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events. Systematic Review Registration: PROSPERO [CRD42024500551].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.